GW Pharmaceuticals (GWP)

Business description

GW Pharmaceuticals is a UK-based speciality pharma company focused on developing cannabinoid medicines. Lead product, Sativex, is marketed in a number of European countries for multiple sclerosis-associated spasticity.

Share price chart

Share chart

Stock data

Market cap.£741.2m
Last close344.000p
High / Low (52 weeks)410.5p / 45.8p
Stock market listingAIM, NASDAQ
Forecast net cash (£m)82.5
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual2.243.9463.9
Relative *0.845.7431.6

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Achillion Achillion Pharmaceuticals
Acorda Therapeutics Active Biotech
Addex Therapeutics Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
Agennix Alchemia
Alexza Pharmaceuticals Algeta
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Alnylam Pharmaceuticals Amarin
AmpliPhi Biosciences Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Arena Pharmaceuticals Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
AVEO Pharmaceuticals Avita Medical
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioAlliance Pharma BioCryst Pharmaceuticals
BioInvent BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron BTG
Can-Fite BioPharma Cardio3 BioSciences
Celldex Therapeutics Cellectis
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen
Clinuvel Consort Medical
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Genfit
Genmab GeoVax
GI Dynamics Gilead Sciences
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunodiagnostic Systems Holdings
ImmuPharma Imperial Innovations
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Ironwood Pharmaceuticals
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
LCA-Vision LeMaitre Vascular
Lifeline Scientific Ligand Pharmaceuticals
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MolMed
Mologen AG MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Omega Diagnostics Group OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo OvaScience
Oxford BioMedica Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prima BioMed
ProMetic Life Sciences Prosensa
Proteome Sciences QRxPharma
Regeneus Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes Stem Cell Therapeutics
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Topotarget Transgene
Trimel Pharmaceuticals UCB
United Drug Vectura
Verastem Verisante Inc
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
WaferGen Biosystems Wilex
Zealand Pharma Zeltia
Ziopharm Oncology

Company news

GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH) Surges

Wed, 23 Apr 2014 17:15:00 GMT

GW Pharmaceuticals PLC- Coverage Initiated at Morgan Stanley (GWPH)

Tue, 22 Apr 2014 12:22:30 GMT

Why Marijuana Stock GW Pharmaceuticals (Nasdaq: GWPH) Is Flying High

Wed, 23 Apr 2014 20:03:45 GMT

Morgan Stanley bullish on GW Pharmaceuticals

Tue, 22 Apr 2014 12:12:24 GMT

Trending STocks: Apple Inc. (NASDAQ:AAPL), GW Pharmaceuticals PLC ...

Thu, 24 Apr 2014 08:32:25 GMT

Y/E Sep Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2012A 33.1 2.8 2.2 2.6 132.3 333.2
2013A 27.3 (8.9) (9.7) (2.6) N/A N/A
2014E 23.7 (15.2) (15.3) (5.5) N/A N/A
2015E 24.4 (15.8) (15.9) (5.5) N/A N/A

Last updated on 27/03/2014

Investment summary

GW Pharmaceuticals is maintaining its momentum, following its $101m fund-raising in January, with the start of two Phase II trials. A 200-patient Phase IIb trial with GWP42004 in Type II diabetes and a Phase IIa trial with GWP42003 in schizophrenia in 80 patients are now underway; data from both studies are due in H215. GW also reported that GWP42006 was well tolerated, with no serious or severe adverse events, during a 66-patient Phase I epilepsy trial. Continued pipeline advances are expected in 2014 and would represent upside. These include initial data from physician-led studies with Epidiolex in children with refractory epilepsy (mid-2014), the start of Phase II Epidiolex trials (2014), Phase III Sativex cancer pain data (Q414) and the US Phase III start in MS spasticity (H214). 2014 remains potentially transformative for GW as its pipeline delivers important clinical milestones.

Last updated on 31/03/2014

Industry outlook

GW is the leader in the field of cannabinoid medicines, which have the potential to become novel therapies for a broad range of diseases. Cannabinoids are diverse chemical compounds that GW extracts from different cannabis plant varieties (chemotypes) it has bred. Sativex is GW’s lead product; we estimate it will achieve 5-10% market share in its approved indications.

Last updated on 31/03/2014

Key management

Geoffrey Guy, Chairman
Justin Gover, CEO
Adam David George, CFO

Company address

6th Floor
1 Cavendish Place
London
W1G 0QF
United Kingdom
+44 (0) 1980 557 000
View website